Original contributionThe pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome☆
Introduction
The lung is the most frequent extramuscular organ afflicted in the idiopathic inflammatory myopathies including polymyositis and dermatomyositis (DM). Clinical respiratory signs and symptoms can derive from respiratory muscle weakness, infectious complications, aspiration due to oropharyngeal dysfunction, or complications of immunosuppressive therapy [1], [2], [3], [4], [5]. The association of interstitial lung disease (ILD) and the myositis spectrum of disease is well known, and the incidence varies depending on the subclassification of the syndrome and autoantibody profiles [6], [7], [8], [9], [10], [11]. The highest incidence occurs in the so-called antisynthetase syndrome (ASS) in which patients have autoantibodies that target aminoacyl transfer RNA synthetases that catalyze the binding of specific amino acids to their cognate transfer RNA during protein synthesis [1]. Patients often present with myositis, ILD, arthritis, Raynaud phenomenon, fever, and mechanic's hands with variations in incidence dependent on the unique antiaminoacyl transfer RNA synthetase antibody [1], [3]. Anti-Jo1 (antihistidyl transfer RNA synthetase) is the most common autoantibody in this group and is associated with pulmonary disease in more than 70% of cases [1], [12]. Others include anti-PL7 (antithreonyl), anti-PL12 (antialanyl), anti-OJ (anti-isoleucyl), anti-EJ (antiglycyl), and anti-KS (antiasparaginyl), among others. Although anti-Jo1 occurs in 20% to 30% of ASSs, the second most common, anti-PL7 (antithreonyl) occurs in 3% to 17% of cases and also has a high incidence of clinical ILD [13], [14], [15], [16], [17], [18], [19]. Despite its relative frequency and its involvement of the lung, the pulmonary pathology of anti-PL7 synthetase syndrome (APL7SS) has been poorly described, with few biopsy reported cases in the literature [13], [14], [15], [16]. In this study, we report the largest study of the pulmonary histopathology of anti-PL7 pulmonary disease in conjunction with a review of the reported biopsy findings in the English literature.
Section snippets
Materials and methods
The University of Pittsburgh Connective Tissue Disease (CTD) Registry encompasses more than 3 decades of prospective data and serum collected on consecutive outpatients and inpatients with various autoimmune diseases evaluated at the University of Pittsburgh [1]. All variables (clinical, laboratory, radiographic, and pathologic) as well as organ system definitions are well defined and standardized in this registry. The antisynthetase antibody group included patients in the CTD registry who were
Clinical presentation
The clinical features of the 8 patients with clinical APL7SS are shown in Table 1. Five patients were women; 3 were men. All except 1 were white. Mean age was 54 years (range, 36-83 years). Most patients presented with cough (n = 5) or dyspnea on exertion (n = 3). Myositis was present in 5 patients based on proximal muscle weakness or abnormal muscle enzymes. Skin changes of DM were noted in 5 patients, and “mechanic's hands” were present in 3. Sclerodactyly was not noted in any patient.
Discussion
Idiopathic inflammatory myopathies such as DM and polymyositis may affect many organs beyond skeletal muscle and skin. Involvement of these other sites is unpredictable but is related to the autoantibodies associated with myopathy. In particular subsets of inflammatory myopathy—the ASSs—are associated with a variety of antibodies directed at the aminoacyl transfer RNA synthetases responsible for the attachment of amino acids to cognate transfer RNA, and they have a high incidence of pulmonary
References (24)
- et al.
Pulmonary manifestations of the idiopathic inflammatory myopathies
Clin Chest Med
(2010) - et al.
Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
Chest
(2010) - et al.
Anti-synthetase syndrome in ANA and anti–Jo-1 negative patients presenting with idiopathic interstitial pneumonia
Respir Med
(2009) - et al.
The pulmonary histopathologic manifestations of the anti–Jo-1 tRNA synthetase syndrome
Mod Pathol
(2010) - et al.
Patients with non–Jo-1 anti–tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
Ann Rheum Dis
(2014) - et al.
Therapeutic approaches in myositis
Curr Rheumatol Rep
(2011) Update on myositis-specific and myositis-associated autoantibodies
Curr Opin Rheumatol
(2000)- et al.
Anti–aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies
Autoimmunity
(2006) - et al.
Interstitial lung disease in polymyositis and dermatomyositis
Curr Opin Rheumatol
(2005) - et al.
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2010)
Common and distinct clinical features in adult patients with anti–aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome
PLoS One
Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls
Curr Opin Rheumatol
Cited by (26)
Myositis-associated interstitial lung disease
2024, Revista Colombiana de ReumatologiaPulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies
2022, Respiratory MedicineCitation Excerpt :Historically, these patients have been considered poor biopsy candidates, and radiographic patterns have often been used to surmise the underlying pathology. However, pulmonary radiographic and biopsy findings often disagree [17–19]. For example, in one series, a CT pattern initially suggestive of fibrotic NSIP in 12 patients correlated with findings of UIP on lung biopsy in 4 of these [77].
Myositis in clinical practice—relevance of new antibodies
2018, Best Practice and Research: Clinical RheumatologyCitation Excerpt :Antisynthetase antibodies have been reported with different patterns of lung pathology. In 8 patients with anti-PL-7, lung histology showed usual interstitial pneumonia (UIP) (n = 4), organizing pneumonia (n = 2), nonspecific interstitial pneumonia (n = 1), and lymphoid interstitial pneumonia (n = 1) [38], while 4 patients with anti-EJ (all amyopathic) demonstrated UIP (n = 2) and organizing diffuse alveolar damage (DAD) (n = 2) [39]. Another series of 5 patients with anti-KS reported UIP (n = 4) and organizing pneumonia (n = 1) [40].
Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease
2016, Respiratory MedicineCitation Excerpt :The current study showed that the anti-ARS-positive, anti-MDA5-positive and MSA-negative groups accounted for a large percentage of PM/DM-ILD patients, whereas few or no PM/DM-ILD patients were positive for MSAs other than anti-ARS and anti-MDA5 antibodies. Anti-ARS or anti-MDA5 antibody-positive patients have been shown to have unique features [14–28,32]. Consistent with these results, we confirmed that there were characteristic clinical features in our PM/DM-ILD cohort.
Pulmonary complications of inflammatory myopathy
2015, Rheumatic Disease Clinics of North AmericaCitation Excerpt :Patients with anti–PL-7 and anti–PL-12 tend to present with a higher incidence of ILD in the absence of clinical myositis.32 A few studies found that usual interstitial pneumonia (UIP) was more common than nonspecific interstitial pneumonia (NSIP) when histopathologic diagnosis was obtained.33,34 Overall, because the other anti-ARS antibodies make up less than 2% of patients with the antisynthetase syndrome, little is known about their specific phenotypes; however, smaller case series highlight the association of several of these less frequently observed anti-ARS antibodies with ILD.35–37
- ☆
Disclosures: There are no conflicts of interest or funding disclosures.